Chase Knickerbocker
Stock Analyst at Craig-Hallum
(4.65)
# 154
Out of 5,090 analysts
47
Total ratings
61.7%
Success rate
33.76%
Average return
Main Sectors:
Stocks Rated by Chase Knickerbocker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HROW Harrow | Maintains: Buy | $54 → $64 | $45.75 | +39.89% | 4 | Sep 23, 2025 | |
| INDV Indivior | Maintains: Buy | $27 → $34 | $35.12 | -3.19% | 5 | Aug 27, 2025 | |
| FENC Fennec Pharmaceuticals | Maintains: Buy | $13 → $14 | $7.55 | +85.43% | 6 | Aug 15, 2025 | |
| PYPD PolyPid | Maintains: Buy | $15 → $13 | $3.97 | +227.46% | 2 | Aug 14, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $6.5 → $11 | $6.51 | +68.97% | 2 | Aug 8, 2025 | |
| DMAC DiaMedica Therapeutics | Maintains: Buy | $8 → $11 | $8.78 | +25.28% | 1 | Jul 18, 2025 | |
| BFLY Butterfly Network | Initiates: Buy | $3 | $3.06 | -1.96% | 1 | Jul 1, 2025 | |
| NRXS NeurAxis | Initiates: Buy | $7 | $2.67 | +162.17% | 1 | Jun 16, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $12 → $17 | $14.58 | +16.60% | 3 | Jun 9, 2025 | |
| ETON Eton Pharmaceuticals | Maintains: Buy | $26 → $28 | $16.26 | +72.20% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $17.68 | +120.59% | 1 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $3.48 | +129.89% | 4 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $21 | $9.78 | +114.72% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $6 | $5.57 | +7.72% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $6.93 | +73.16% | 2 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $7.01 | +42.65% | 1 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $23 | $21.34 | +7.78% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1 → $1.2 | $0.62 | +94.81% | 2 | Jul 11, 2023 |
Harrow
Sep 23, 2025
Maintains: Buy
Price Target: $54 → $64
Current: $45.75
Upside: +39.89%
Indivior
Aug 27, 2025
Maintains: Buy
Price Target: $27 → $34
Current: $35.12
Upside: -3.19%
Fennec Pharmaceuticals
Aug 15, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $7.55
Upside: +85.43%
PolyPid
Aug 14, 2025
Maintains: Buy
Price Target: $15 → $13
Current: $3.97
Upside: +227.46%
Xeris Biopharma Holdings
Aug 8, 2025
Maintains: Buy
Price Target: $6.5 → $11
Current: $6.51
Upside: +68.97%
DiaMedica Therapeutics
Jul 18, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $8.78
Upside: +25.28%
Butterfly Network
Jul 1, 2025
Initiates: Buy
Price Target: $3
Current: $3.06
Upside: -1.96%
NeurAxis
Jun 16, 2025
Initiates: Buy
Price Target: $7
Current: $2.67
Upside: +162.17%
Phathom Pharmaceuticals
Jun 9, 2025
Maintains: Buy
Price Target: $12 → $17
Current: $14.58
Upside: +16.60%
Eton Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $26 → $28
Current: $16.26
Upside: +72.20%
Feb 28, 2025
Initiates: Buy
Price Target: $39
Current: $17.68
Upside: +120.59%
Jan 22, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $3.48
Upside: +129.89%
Jan 17, 2025
Maintains: Buy
Price Target: $18 → $21
Current: $9.78
Upside: +114.72%
Jan 17, 2025
Maintains: Buy
Price Target: $5 → $6
Current: $5.57
Upside: +7.72%
Aug 1, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $6.93
Upside: +73.16%
Jul 11, 2024
Initiates: Buy
Price Target: $10
Current: $7.01
Upside: +42.65%
May 9, 2024
Maintains: Buy
Price Target: $22 → $23
Current: $21.34
Upside: +7.78%
Jul 11, 2023
Maintains: Buy
Price Target: $1 → $1.2
Current: $0.62
Upside: +94.81%